Patient and caregiver commitment, together with imaging and appropriate clinical assessments, determine developmental success in neurology indications. That’s why Worldwide focuses on study designs that offer less hassle for families, and science that leaves less subjectivity for interpreting efficacy.
When you have a neurology program to develop, you want a service provider that performs above the rest in its ability to deliver a great experience on a reasonable budget. You want data quality and innovative design approaches that deserve your loyalty.
Our neurology team unites thoughtful logistics with a patient-forward strategy that demonstrates their in-depth knowledge of the therapeutic area. Our experts can boost the strength of your program through technology and design approaches right from the start, providing the ideal imaging and outcome measures to drive success for the life of your program.
Anne-Claude has more than 20 years’ clinical research experience within both contract research organizations and pharmaceutical companies. She has managed global programs and business development activities, as well as strategic oversight, and specializes in psychiatry and neurology. Her experience includes a variety of indications in psychiatry and neurology (multiple sclerosis, acute ischemic stroke, agitation in Alzheimer’s disease patients, epilepsy, schizophrenia, major depressive disorder, generalized anxiety disorder, sleep, and neuropathic pain) and spans the full spectrum of Phase I-IV services. She has directed a large pivotal program of seven studies in Phase II and Phase III in schizophrenia and served as the customer Portfolio Lead for a multiple sclerosis program, providing operational strategy for the development plan and overseeing the delivery of clinical programs for several compounds.
Tom is a therapeutic leader in neurology medical and scientific affairs, with experience in both industry and academia. Tom is a board-certified neurologist and affiliate professor of clinical neurology. At Worldwide, he is responsible for the scientific and medical leadership of global neurology clinical research initiatives. He is involved with protocol design and development and clinical analysis for randomized controlled clinical trials in populations with early and advanced Parkinson’s disease, Alzheimer’s disease, multiple sclerosis, epilepsy, stroke, migraine, and neurodegenerative disorders. He works to implement up-to-date, evidence-based science across Worldwide’s portfolio of clinical drug research and development projects.
Tamara Ast, PhD, Senior Vice President for Project Delivery Services in Neuroscience at Worldwide Clinical Trials, oversees a team of experienced neuroscience clinical research professionals for neurological, psychiatric, and pain indications. With more than 20 years’ industry experience, she has provided leadership for project management and operations delivery at Worldwide. Her affinity for working in multicultural environments has contributed to her commitment to diversity. She empowers large teams across multiple regions globally to deliver regulatory, scientific, medical, and operational excellence to our customers.
Richard Bennett is Senior Director and Therapeutic Strategy Lead in the Neuroscience franchise at Worldwide Clinical Trials. With two decades in the industry, he has advanced through the traditional clinical operations roles such as clinical research associate and clinical trial manager and has spent many years as a leader of clinical development programs in both the larger pharma and biotech setting. He has worked on neuromuscular disorders, rare diseases, critical care, pain and palliative care, dermatology, and epidemiology programs. His direct experience working with large pharma and small and emerging biotech firms has given him a deep understanding of the needs of our sponsors.
Does genotypic vs. phenotypic segmentation make sense in the context of an amyotrophic lateral sclerosis (ALS) study?Learn More
A case study in Multiple Sclerosis.Learn More
Watch this webinar to learn how to overcome hurdles in your early Parkinson’s drug development.Learn More
Our medical, scientific and operational teams include seasoned neurologists and neuroscientists working closely to drive impeccable operational study execution, for everything from first-in-human to large, global Phase III programs.
From Parkinson’s and multiple sclerosis to epilepsy and amyotrophic lateral sclerosis, Worldwide has done it all. We’ve worked with stimulants, selective inhibitors, reuptake inhibitors, neurotoxin proteins, long-acting injectables, and much more.
Years of experience in neurology mean years of experience working with global vendors and sites to develop a trusted, at-the-ready network of investigators and others who excel in neurology study recruitment, data collection, start-up timelines, and quality.
Worldwide is one of the few full-service CROs that provides integrated rater training, scale management, bespoke assessment development, and management of electronic Clinical Outcome Assessments (eCOA) vendors, to help you reliably demonstrate efficacy.
Worldwide began as a neurology-focused CRO, and we pair our long-standing expertise and strong heritage with a flexibility and nimbleness to adapt to your study’s unique needs and to advance neurology research.
Our Cognitive Task Force and scale development work speak volumes about our commitment to Alzheimer’s and dementia research. At Worldwide, we design and execute rigorous, compassionate studies we’d be happy to have our own family and friends take part in, carefully protecting the patient experience and maintaining compelling data integrity to get products to market even in this competitive research space.Learn More
Worldwide leads the way in best practice development for pain and addiction research. We have seen it all, which helps us offer the right blend of tried-and-true logistics, creative study designs, and thoughtful outcomes measures to augment objectivity in this otherwise nebulous field of research.Learn More
Rare neurological diseases each have unique hurdles for developing compelling outcomes assessments that can demonstrate efficacy with small patient populations. Worldwide is a leader in rare disease recruitment, novel endpoint development, and innovative study designs. We deliver specialty studies that apply our overarching knowledge in neurological conditions and rare diseases to thoughtful study designs, respecting patient communities and generating the data sponsors need to advance their compound to market.Learn More
A crowded research space makes it difficult to weed the subjectivity out of the science—which demands a CRO with psychiatry know-how from the ground up and the top down. Our proven track record for patient recruitment and engaged investigator networks speaks volumes about our expertise in psychiatric trial development and execution.Learn More
Senior Director, Therapeutic Strategy Lead, Neuroscience
Vice President, Central Nervous System Therapeutic Area Lead, Medical Affairs
Chief Development Officer
Executive Director, Project Management, Psychiatry and Neuroscience Rare Diseases
Senior Vice President, Project Management, Neuroscience
Executive Director, Project Management, Franchise Area Lead, Analgesia, Addiction, and Neurology Rare Disorders
Vice President, Scientific Solutions, Neuroscience
Executive Director, Project Management, Alzheimer’s Disease and other Dementias
Executive Director, Project Management, Neurology and Rare Diseases
Chief Medical and Scientific Officer
Vice President, Project Management, Psychiatry, Alzheimer’s Disease and other Dementias
Vice President, Neuroscience, Scientific Solutions
Executive Director, Project Management, Alzheimer’s Disease and other Dementias
Global Head of Regulatory Strategy
Vice President, Project Management, Psychiatry and Neurology
Senior Vice President, Medical & Scientific Affairs
Senior Director of Clinical Projects, Clinical Assessment Technologies